According to Assertio Therapeutics 's latest financial reports and stock price the company's current price-to-earnings ratio (TTM) is 0.4412. At the end of 2022 the company had a P/E ratio of 1.88.
Year | P/E ratio | Change |
---|---|---|
2022 | 1.88 | -101.72% |
2021 | -109 | 3760.42% |
2020 | -2.82 | 584.42% |
2019 | -0.4125 | -106.63% |
2018 | 6.22 | -226.03% |
2017 | -4.94 | -60.53% |
2016 | -12.5 | -12.34% |
2015 | -14.3 | -299.38% |
2014 | 7.16 | -49.24% |
2013 | 14.1 | -223.06% |
2012 | -11.5 | -394.32% |
2011 | 3.89 | -95.1% |
2010 | 79.5 | -1120.45% |
2009 | -7.79 | 51.09% |
2008 | -5.16 | -258.17% |
2007 | 3.26 | -191.66% |
2006 | -3.56 | -62.06% |
2005 | -9.38 | 33.68% |
2004 | -7.01 | 23.64% |
2003 | -5.67 | 166.58% |
2002 | -2.13 | -43.88% |
2001 | -3.79 |
Company | P/E ratio | P/E ratio differencediff. | Country |
---|---|---|---|
-0.9953 | -325.59% | ๐บ๐ธ USA | |
-5.76 | -1,405.45% | ๐บ๐ธ USA |
The Price/Earnings ratio measures the relationship between a company's stock price and its earnings per share. A low but positive P/E ratio stands for a company that is generating high earnings compared to its current valuation and might be undervalued. A company with a high negative (near 0) P/E ratio stands for a company that is generating heavy losses compared to its current valuation.
Companies with a P/E ratio over 30 or a negative one are generaly seen as "growth stocks" meaning that investors typically expect the company to grow or to become profitable in the future.
Companies with a positive P/E ratio bellow 10 are generally seen as "value stocks" meaning that the company is already very profitable and unlikely to strong growth in the future.